We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Definitive Tests for Irritable Bowel Syndrome Developed

By LabMedica International staff writers
Posted on 24 May 2015
Print article
Image: IBSchek Blood Test kit for irritable bowel syndrome (Photo courtesy of Commonwealth Laboratories Inc.).
Image: IBSchek Blood Test kit for irritable bowel syndrome (Photo courtesy of Commonwealth Laboratories Inc.).
In the clinical evaluation of chronic diarrhea, common differential diagnoses include diarrhea-predominant irritable bowel syndrome (D-IBS), inflammatory bowel disease (IBD) and celiac disease.

Although the anti-tissue transglutaminase antibody (anti-tTG) has proven to be an excellent biomarker for identifying celiac disease, D-IBS remains a diagnosis of exclusion since the clinical criteria for IBS, do not exclude IBD.

Scientists at Cedars-Sinai Medical Center (Los Angeles, CA, USA) and their collaborators recruited a total of 2,681 subjects. This included 2,375 D-IBS subjects, 43 healthy subjects, 121 celiac and 142 IBD subjects which included 73 with Crohn’s and 69 ulcerative colitis patients. IBS subjects were on average 3.9 years older than the non-IBS groups. There were no differences in sex distribution of IBS and non-IBS subjects; however, percentage of females was greater in the healthy controls, IBS and celiac groups as compared with the IBD group.

Plasma was collected from all subjects and tested by enzyme-linked immunosorbent assay for antibodies to cytolethal distending toxin B (CdtB) and vinculin. Tetramethylbenzidine (TMB) substrate solution was used for visualization and immediately read on a BioTek Synergy HT plate reader (Winooski, VT, USA). The optical densities (OD) were read for 90 minutes at 370 nm and used to compare levels of anti-CdtB or anti-vinculin. Raw OD values were used for the data analysis.

Using optical density levels, anti-CdtB antibody levels in D-IBS subjects were 2.53 ± 0.69 which were significantly higher than healthy subjects at 1.81 ± 0.73, Crohn’s disease at 1.72 ± 0.81, ulcerative colitis at 1.54 ±0.68 and celiac disease at 2.23±0.70. There were no differences in anti-CdtB levels between healthy subjects and IBD subjects; however, subjects with celiac disease had higher anti-CdtB levels than all other non-IBS groups. The tests are marketed under the name IBSchek and are produced by Commonwealth Laboratories Inc. (Salem, MA, USA).

Mark Pimentel, MD, who created the tests and is the senior author of the study, said, “Having an early diagnosis means patients can avoid years of invasive tests and visits to specialists that often leave them with more questions than answers. With these new blood tests, many patients will now be able to proceed right to therapy for their condition.” The study was published on May 13, 2015, in the journal Public Library of Science ONE.

Related Links:

Cedars-Sinai Medical Center 
BioTek 
Commonwealth Laboratories Inc.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.